Flash Finance

Fermenta Biotech Ltd506414Corporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹468.85
MCap ₹1,313 Cr · P/E 20.5
Fermenta Biotech Ltd — Stock analysis & AI research Fermenta Biotech Ltd — Multibagger AI analysis Fermenta Biotech Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹112 Cr
Sales · Jun 2026
-6.0% YoY
₹23 Cr
Operating Profit · Jun 2026
-0.1% YoY
20.5%
OPM % · Jun 2026
+6.2% YoY
₹15 Cr
Net Profit · Jun 2026
-6.3% YoY
₹5.23
EPS · Jun 2026
-5.1% YoY

📝 Fermenta Biotech Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Fermenta Biotech Ltd reported revenue of ₹112 crore for the quarter ended June 2026 (Q1 FY27), down 6.0% from ₹119 crore in the same quarter last year, and up 1.7% sequentially over the March 2026 quarter.

Net profit fell 6.3% year-on-year to ₹15 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹5.23.

Operating profit stood at ₹23 crore — an operating margin (OPM) of 20.5%, compared with 19.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Fermenta Biotech Ltd posted revenue of ₹450 crore, a growth of 4.4% over FY25, with a net profit of ₹65 crore (down 3.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹443 crore with a net profit of ₹64 crore.

Valuation snapshot

At the current price of ₹468.85, 506414 has a market capitalisation of ₹1,313 crore and a trailing P/E of about 20.5.

Within the Pharmaceuticals industry, it is the 7th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 64.08%, foreign institutional investors (FIIs) 0.02%, public shareholders 33.32% of Fermenta Biotech Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,313 Cr
Current Price ?
₹468.9
P/E ?
20.52below ind
Industry P/E ?
22.40
P/B ?
3.11
P/S ?
2.96
P/FCF ?
25.25
Enterprise Value ?
₹1,426 Cr
EV/EBITDA ?
15.67
PEG ?
0.12
Earnings Yield ?
5.0%
Dividend Yield ?
0.80%
Profitability & Returns
Sales (TTM) ?
₹443 Cr
OPM ?
20.5%
Profit after tax (TTM) ?
₹64 Cr
EPS (TTM) ?
₹22.85
ROCE ?
18.0%
ROE ?
15.2%
ROA ?
9.8%
Growth
Sales — latest qtr ?
₹112 Cr
PAT — latest qtr ?
₹15 Cr
YoY qtr sales growth ?
-6.0%
YoY qtr profit growth ?
-6.3%
Sales growth (3y) ?
11%
Sales growth (5y) ?
4%
Profit growth (3y) ?
168%
Profit growth (5y) ?
3%
Financial Health
Debt ?
₹113 Cr
Debt to Equity ?
0.27
Interest Coverage ?
5.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
64.08%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
47.2%
Return 6 months ?
33.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 101775189907390146122119107114110112 -6.0% +1.7%
Operating Profit 2513-1226921550332323232223 -0.1% +4.4%
Other Income -142-7323324961155 -45.6% -67.4%
Interest 65453344333333 -15.4% -15.4%
Depreciation 66666666665555 -13.6% +3.7%
Profit Before Tax -15-28181-5942282321172920 -12.4% -30.5%
Net Profit -25-2812-7-5835291615122215 -6.3% -31.9%
EPS -0.721.63-9.513.98-2.46-1.652.7711.899.965.515.004.007.335.23 -5.1% -28.6%
OPM % 24.8% 16.9% -23.5% 29.2% 10.0% 2.7% 16.7% 34.2% 27.0% 19.3% 21.5% 20.2% 20.0% 20.5% +6.2% +2.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹431 Cr ₹450 Cr ₹443 Cr +4.4%
Operating Profit ₹100 Cr ₹91 Cr ₹91 Cr -9.0%
OPM % 23.20% 20.22% 20.54% -12.8%
NPM % 15.55% 14.44% 14.45% -7.1%
Other Income ₹12 Cr ₹31 Cr ₹27 Cr +158.3%
Depreciation ₹24 Cr ₹21 Cr ₹20 Cr -12.5%
Interest ₹14 Cr ₹12 Cr ₹12 Cr -14.3%
EBIT ₹76 Cr ₹70 Cr ₹71 Cr -7.9%
PBT ₹74 Cr ₹90 Cr ₹87 Cr +21.6%
Tax — — ₹5 Cr —
Net Profit ₹67 Cr ₹65 Cr ₹64 Cr -3.0%
EPS ₹22.97 ₹21.84 ₹21.56 -4.9%
Material Cost — — ₹46 Cr —
Employee Cost — — ₹20 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141514 -6.7%
Reserves 322300365408 +11.8%
Borrowings 219139115113 -1.7%
Other Liabilities 108112128116 -9.4%
Total Liabilities 664565622652 +4.8%
Fixed Assets 257267226220 -2.7%
CWIP 4521613 -18.8%
Investments 154412 +200.0%
Other Assets 347293377408 +8.2%
Total Assets 664565622652 +4.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1241053483 +144.1%
Cash from Investing Activity -63-150-44 —
Cash from Financing Activity -41-91-51-42 +17.6%
Net Cash Flow 19-1-17-4 +76.5%
Free Cash Flow 83863152 +67.7%
CFO/OP 304%276%35%109% +211.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 7592102111 +8.8%
Inventory Days 317272249311 +24.9%
Days Payable 150184169151 -10.7%
Cash Conversion Cycle 242180182271 +48.9%
Working Capital Days -192551122 +139.2%
ROCE % 4%4%20%18% -10.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 64.08%64.08%64.08%64.08% +0.0%
FIIs 0.02%0.02%0.02%0.02% +0.0%
Public 35.00%34.75%33.99%33.32% -2.0%
Others 0.89%1.14%1.90%2.58% +35.8%
No. of Shareholders 12,84513,76014,13913,661 -3.4%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Fermenta Biotech Ltd's revenue in Q1 FY27?
Fermenta Biotech Ltd reported revenue of ₹112 crore for the quarter ended June 2026 (Q1 FY27), down 6.0% from ₹119 crore in the same quarter last year, and up 1.7% sequentially over the March 2026 quarter.
What was Fermenta Biotech Ltd's net profit in Q1 FY27?
Net profit fell 6.3% year-on-year to ₹15 crore, from ₹16 crore. Earnings per share (EPS) came in at ₹5.23.
What is 506414's market capitalisation and P/E ratio?
At the current price of ₹468.85, 506414 has a market capitalisation of ₹1,313 crore and a trailing P/E of about 20.5.
Who owns Fermenta Biotech Ltd? (shareholding pattern)
As of Mar 2026, promoters held 64.08%, foreign institutional investors (FIIs) 0.02%, public shareholders 33.32% of Fermenta Biotech Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI